diagnosis

Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML

Original Publication Date
Article Source
External Web Content
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut, discusses updated results from an ongoing retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in patients with relapsed/refractory…

A Caregiver's Story: MDS Diagnosis Changes their Lives

I know my fiancé well.  Even though he seemed to be healthy and his job kept him active, I knew it had been a long time since he had a medical physical, so I pushed him into an appointment.

Without symptoms, the doctor suggested routine blood work as a part of the physical.  We were surprised that all his counts were low.  The doctor decided to check again in a month, so I made sure that his diet was healthier and that he took vitamins, hoping that would correct any problem.  

Precision Medicine Approach Deemed Safe, Feasible for Older Patients With Untreated AML

Original Publication Date
Article Source
External Web Content
A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated acute myeloid leukemia (AML), according to a study published in Nature Medicine. Investigators also found that delaying…

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

Original Publication Date
Article Source
External Web Content
TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival. Across TP53-altered MDS and AML…

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Original Publication Date
Article Source
External Web Content
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk…

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

Original Publication Date
Article Source
External Web Content
Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area. Significant disparities were found…

Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine

Original Publication Date
Article Source
External Web Content
Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia. John C. Byrd, MD Delaying treatment for up to 7 days so that genomic…

Guang-Shing Cheng, M.D.

Institution
Fred Hutchinson Cancer Research Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Graft Versus Host Disease (GVHD)
About
Dr. Guang-Shing Cheng is Associate Professor in the Clinical Research Division at Fred Hutch in Seattle. Dr. Cheng is a pulmonologist who focuses on improving outcomes for cancer patients who have respiratory failure and lung complications related to their cancer treatments. She is developing new ways to prevent lung damage and improve lung function in these patients. Dr. Cheng’s main interest is bronchiolitis obliterans syndrome, a serious complication of blood stem cell transplantation. She also studies the role of respiratory viruses and other infectious pathogens in lung disease in

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.